We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

[NAIROBI] Two South African researchers have been awarded the inaugural Olusegun Obasanjo Prize for scientific discovery and technological innovation, for their work on HIV/AIDS and herpes prevention.

Salim S. Abdool Karim and Quarraisha Abdool Karim, a husband-and-wife research team from the University of Kwazulu-Natal, received the award earlier this month (10 November) for their work on the use of a vaginal microbicide gel containing tenofovir — the culmination of 17 years of research into microbicides. The gel was found to be 39 per cent effective in reducing HIV transmission, above the statistically significant result of 33 per cent.

They also found that it appeared to have a dual effect, protecting against herpes simplex virus-2.

The prizerewards African scientists who have made outstanding achievements in scientific discovery or technological innovation. It is named after former Nigerian president, Olusegun Obasanjo, who attended the ceremony at the African Academy of Sciences (AAS) in Nairobi, Kenya.

Salim Abdool Karim told SciDev.Net: "Quarraisha and I are humbled to be the recipients of the Obasanjo Prize. We see this as an award not for us but for the success of a superb collaboration between the Center for the Aids Programme of Research in South Africa; the University of KwaZulu-Natal,South Africa; Columbia University, United States;CONRAD; FHI 360 (formerly Family Health International); and Gilead Sciences.

"This award is an important milestone in my career as a scientist, and I am very thankful to the AAS for [it]," Karim added.

He said that women bear the brunt of the HIV epidemic in southern Africa and that tenofovir gel is the first prevention method to empower them directly to control the risk of HIV infection.

"I hope that this award will bring greater attention to the plight of the HIV epidemic for young women in Africa. We need greater efforts and greater resources to find ways to empower women to protect themselves against HIV infection in Africa," he said.

The prize comprises a certificate, a gold medal and US$5,000. Applicants' research should be in the fields of biotechnology, energy, information and communications technology or materials science.

Berhanu Abegaz, executive director of the AAS, said that the prize will help motivate scientific research in Africa; encourage young scientists to prioritise high-quality, relevant science and technology; and maybe help keep young scientists on the continent.

Shem O. Wandiga, managing trustee at the Centre for Science and Technology Innovations, in Kenya, said the prize will motivate many Africans to do quality work that improves the lives of their people.

"With time it may turn out to be the equivalent of a Nobel Prize for Africa," he said.